When I first read about the B-OM end of Phase II meeting with the FDA scheduled for later this quarter, my first thought was that a BP would want to know the outcome of that meeting before finalizing a deal for B-OM and IBD. They will have a much better idea of what the costs will be to move B-OM forward once that happens, so why not wait six to eight weeks to find out what the next steps are? Is my thinking flawed?